|
Variables
|
Overall (N = 4331)
|
NG (N = 776)
|
Pre-DM (N = 1163)
|
DM (N = 2392)
|
p-value
|
|---|
|
Age, years
|
58.32 ± 12.29
|
54.93 ± 9.91
|
59.55 ± 17.36
|
58.82 ± 9.50
|
< 0.001
|
|
Male, n (%)
|
3078 (71.1)
|
594 (76.5)
|
802 (69.0)
|
1682 (70.3)
|
0.001
|
|
BMI, kg/(m2)
|
25.85 ± 3.10
|
25.34 ± 3.12
|
25.83 ± 3.10
|
26.23 ± 3.03
|
< 0.001
|
|
Family history of CAD, n (%)
|
608 (14.0)
|
128 (16.5)
|
152 (13.1)
|
328 (13.7)
|
0.082
|
|
Smoking, n (%)
|
2343 (54.1)
|
412 (53.1)
|
636 (54.7)
|
1317 (55.1)
|
0.003
|
|
Drinking, n (%)
|
1425 (32.9)
|
273 (35.2)
|
363 (31.2)
|
789 (33.0)
|
0.189
|
|
Hypertension, n (%)
|
2845 (65.7)
|
494 (63.7)
|
746 (64.1)
|
1605 (67.1)
|
0.058
|
|
FPG, mmol/L
|
6.37 ± 1.99
|
4.79 ± 0.42
|
6.62 ± 2.12
|
6.77 ± 1.93
|
0.006
|
|
HbA1C, %
|
6.67 ± 1.22
|
5.37 ± 0.23
|
6.02 ± 0.25
|
7.40 ± 1.31
|
0.002
|
|
TC, mmol/L
|
4.08 ± 1.05
|
4.01 ± 1.01
|
4.04 ± 1.04
|
4.11 ± 1.06
|
0.02
|
|
HDL-C, mmol/L
|
1.06 ± 0.29
|
1.07 ± 0.31
|
1.04 ± 0.28
|
1.06 ± 0.29
|
0.033
|
|
Non-HDL-C, mmol/L
|
2.89 (2.3–3.59)
|
2.78 (2.21–3.53)
|
2.88 (2.34–3.57)
|
2.92 (2.31–3.64)
|
0.013
|
|
LDL-C, mmol/L
|
2.44 ± 0.89
|
2.38 ± 0.87
|
2.43 ± 0.87
|
2.46 ± 0.91
|
0.081
|
|
TG, mmol/L
|
1.46 (1.09–2.02)
|
1.36 (0.99–1.89)
|
1.46 (1.12–2.02)
|
1.50 (1.11–2.06)
|
0.002
|
|
CRC, mmol/L
|
0.52 (0.36–0.73)
|
0.48 (0.34–0.68)
|
0.52 (0.36–0.73)
|
0.54 (0.37–0.75)
|
0.001
|
|
MRC, mmol/L
|
0.50 (0.36–0.69)
|
0.47 (0.34–0.66)
|
0.48 (0.36–0.67)
|
0.52 (0.37–0.71)
|
< 0.001
|
|
Lp(a), mg/dL
|
15.10 (6.72–36.12)
|
14.92 (6.91–35.71)
|
14.86 (6.42–34.04)
|
15.35 (6.87–37.35)
|
0.334
|
|
ApoA1, g/L
|
1.33 ± 0.29
|
1.32 ± 0.31
|
1.33 ± 0.28
|
1.33 ± 0.29
|
0.685
|
|
ApoB, g/L
|
0.91 ± 0.29
|
0.89 ± 0.28
|
0.91 ± 0.27
|
0.91 ± 0.30
|
0.356
|
|
HsCRP, mg/L
|
1.36 (0.74–2.87)
|
1.09 (0.62–2.36)
|
1.41 (0.77–2.96)
|
1.45 (0.77–3.06)
|
0.001
|
|
Baseline statin use, n (%)
|
2621 (60.5)
|
457 (58.9)
|
681 (58.6)
|
1483 (62.0)
|
0.085
|
|
Baseline ezetimibe use, n (%)
|
463 (10.7)
|
76 (9.8)
|
120 (10.3)
|
267 (11.2)
|
0.502
|
|
Follow-up statin, n (%)
|
4201 (97.0)
|
745 (96.0)
|
1132 (97.3)
|
2324 (97.2)
|
0.323
|
|
Antidiabetic drug
|
|
OADs, n (%)
|
1468 (33.9)
|
–
|
–
|
1468 (61.4)
|
–
|
|
Insulin, n (%)
|
789 (18.2)
|
–
|
–
|
789 (33.0)
|
–
|
- Data are expressed as the mean value ± SD, median with 25th and 75th or number (%)
- NG, normoglycemia; DM, diabetes mellitus; BMI, body mass index; CAD, coronary artery disease; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; CRC, calculated remnant cholesterol; MRC, measured remnant cholesterol; Lp(a), lipoprotein (a); ApoA1, apolipoprotein A 1; ApoB, apolipoprotein B; hsCRP, high sensitivity C-reactive protein; OADs, Oral antidiabetic agents
